NASDAQ:TLSATiziana Life Sciences Stock Price, Forecast & News

Tiziana Life Sciences' stock was trading at $3.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TLSA shares have increased by 45.1% and is now trading at $5.73. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tiziana Life Sciences.

1 Wall Street analysts have issued 12 month price objectives for Tiziana Life Sciences' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Tiziana Life Sciences' share price to reach $20.00 in the next year. This suggests a possible upside of 249.0% from the stock's current price. View analysts' price targets for Tiziana Life Sciences.

News stories about TLSA stock have trended very negative this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tiziana Life Sciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutTiziana Life Sciences.

Some companies that are related to Tiziana Life Sciences include Corbus Pharmaceuticals (CRBP), Mersana Therapeutics (MRSN), Syndax Pharmaceuticals (SNDX), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), AnaptysBio (ANAB), Clovis Oncology (CLVS), Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Trillium Therapeutics (TRIL), Passage Bio (KROS), Xenon Pharmaceuticals (XENE), Atreca (BCEL) and NewLink Genetics (NLNK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Crispr Therapeutics (CRSP), Micron Technology (MU), Vaxart (VXRT), Agile Therapeutics (AGRX), NVIDIA (NVDA), Occidental Petroleum (OXY), VBI Vaccines (VBIV) and vTv Therapeutics (VTVT).

(TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."

Tiziana Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include HighTower Advisors LLC (4.45%) and Capital Asset Advisory Services LLC (0.06%).

TLSA stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC.

TLSA stock was bought by a variety of institutional investors in the last quarter, including Capital Asset Advisory Services LLC.

Shares of TLSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TLSA stock can currently be purchased for approximately $5.73.

Tiziana Life Sciences has a market capitalization of $147.19 million.

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7495-2379 or via email at [email protected]